| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Psyence Partners with iNGENū for Palliative Care Clinical Trial
Health Canada Oks Clinical-Grade MDMA Export To UK Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its m...
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in ...
Psyence Group Inc.
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedel...
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private place...
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.